Kura Oncology Inc (KURA NASDAQ) stock market data APIs
$12.7745
0.23(1.8%)
as of August 28, 2026
Try our APIs with
free plan!
Kura Oncology Inc Financial Data Overview
Price chart is built with
Anychart
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Prev. Close
12.7745
Open
13.0081
High
13.2066
Low
12.7056
52 wk Range
7.3575-13.9
Market Cap
1 173 M
Shares Outstanding
88 961 K
Revenue
77 225 K
EPS
-0.77
Beta
0.381
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kura Oncology Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kura Oncology Inc data using free add-ons & libraries
Get Kura Oncology Inc Fundamental Data
Kura Oncology Inc Fundamental data includes:
- Net Revenue: 77 225 K
- EBITDA: -316 799 008
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.89
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kura Oncology Inc News
New
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
An updated edition of the July 8, 2026, article. The global oncology market is undergoing significant transformation, driven by the rising burden of cancer, aging populations and rapid advances in me...
Company News for Aug 26, 2026
Shares of DICK'S Sporting Goods, Inc. (DKS) plummeted 30.7% after the company reported second-quarter fiscal 2026 earnings of $3.53 per share, missing the Zacks Consensus Estimate of $3.78 per share. ...
The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today
Medical research scientist working with microscope in modern laboratory by snowing12 via Adobe Stock Kura Oncology (KURA) stock soared on Aug. 25 after a regulatory filing confirmed that CEO Troy Wil...
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
Troy Edward Wilson, the President, Chairman, and CEO of Kura Oncology, Inc. (NASDAQ:KURA), purchased ~100,000 shares of common stock on August 24, 2026. SEC Form 4 filing. Company snapshot Sector: H...
Get Kura Oncology Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
